607 / 1835
PD1/PD-L1 in DLBCL
►
Investigation of nivolumab (anti PD-1), pembrolizumab (anti PD-1),
avelumab (PD-1), durvalumab (anti PD-L1) and atezoluimumab (PD-L1),
in DLBCL
►
PD-L1 expressed on about 30% of patients with DLBCL (more frequent in
PMBL)
►
High is EBV +ve DLBCL and TCRLCL
(Chen et al. Clin Canc Res 2013)
►
Nivoulumab ORR DLBCL 36% (n=11) median duration of response 22
weeks
(Lesokhin et al. ASH 2014)
►
Is PD-L1 expression a biomarker of activity
(Chen et al. Clin Canc Res 2013)